For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Actinium Pharmaceuticals (ATNM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Actinium Pharmaceuticals is a member of our Medical group, which includes 817 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 10.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATNM has moved about 7.63% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.96% on average. This shows that Actinium Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 1.07% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Actinium Pharmaceuticals (ATNM - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Actinium Pharmaceuticals is a member of our Medical group, which includes 817 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ATNM is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ATNM's full-year earnings has moved 10.39% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ATNM has moved about 7.63% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.96% on average. This shows that Actinium Pharmaceuticals is outperforming its peers so far this year.
Looking more specifically, ATNM belongs to the Medical - Drugs industry, a group that includes 171 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have lost 1.07% this year, meaning that ATNM is performing better in terms of year-to-date returns.
ATNM will likely be looking to continue its solid performance, so investors interested Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ATNM - FREE